Entdoc, remember how it was the first l NSCLC trial that first sent a disappointment to PPHM investors when it was determined that the Progression Free Survival statistics were unusually high in the control arm, making the Bavi arm look only marginally better? There were those scans that became controversial when the doctors in the field characterized the reads a little different than the doctors from the independent reviewer. At the time, we on this board began to focus on how survival cannot be manipulated and MOS or OS should be the Bavi success focal point.
We are now looking at 17 or 18 months for MOS results from that first stage NSCLC trial. That would be even more dramatic than the doubling of MOS indicated from the 2nd line NSCLC trial that had to be withdrawn after the coding error was called out by PPHM. Will there by a hand of manipulation transparent then or will parties step aside and allow PPHM technology to stand on its own merits?
I wonder what role, if any, the class action suit law firms exerted in this whole process? That is, at least, the first one that came forward? Mom and Pop may not take to something, but the financial system carries a lot of boats up or down when the tides rise or fall.
Best wishes and IMO.
KT
News 
Market Data 
Discover 
AI
